ReviewThrombosis research2020
COVID-19 versus HIT hypercoagulability.
Review in Thrombosis research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis.Clinical and experimental medicine · 2022Pooled it
- Atypical memory B cell clonal expansion and inflammatory programs associate with platelet-activating antibody development in COVID-19.JCI insight · 2026Article
- Portal-splenic-mesenteric venous thrombosis in COVID-19 patients: a systematic review.Jornal vascular brasileiro · 2025Review
- The Binding of the SARS-CoV-2 Spike Protein to Platelet Factor 4: A Proposed Mechanism for the Generation of Pathogenic Antibodies.Biomolecules · 2024Article
- Prognostic markers in patients with COVID-19 requiring intensive care support.Journal of Taibah University Medical Sciences · 2023Article
- A neutralizable dimeric anti-thrombin aptamer with potent anticoagulant activity in mice.Molecular therapy. Nucleic acids · 2023Article
- FcFrontiers in cardiovascular medicine · 2023Review
- Ischemic Stroke Due to Heparin-induced Thrombocytopenia during Severe COVID-19 Infection.Internal medicine (Tokyo, Japan) · 2022Article
- Hypercoagulability in COVID-19: from an unknown beginning to future therapies.Medicine and pharmacy reports · 2022Review
- Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination.Circulation research · 2022Review
- Necrotizing pancreatitis with portal vein thrombosis in young patient with COVID-19.Journal of infection and public health · 2022Article
- The FCGR2A rs1801274 polymorphism was associated with the risk of death among COVID-19 patients.Clinical immunology (Orlando, Fla.) · 2022Article
- COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art.Current cardiology reviews · 2022Article
- The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19.Frontiers in immunology · 2022Review
- Platelet in thrombo-inflammation: Unraveling new therapeutic targets.Frontiers in immunology · 2022Review
- Mechanisms of Immunothrombosis by SARS-CoV-2.Biomolecules · 2021Review
- Distal arteriovenous fistula to preserve patency in COVID-19-associated acute limb ischemia.Seminars in vascular surgery · 2021Article
- How we approach thrombosis risk in children with COVID-19 infection and MIS-C.Pediatric blood & cancer · 2021Article
- COVID-19-related laboratory coagulation findings.International journal of laboratory hematology · 2021Review
- COVID-19 in thrombosis research: An editorial perspective.Thrombosis research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A striking feature of COVID-19 is the high frequency of thrombosis, particularly in patients who require admission to intensive care unit because of respiratory complications (pneumonia/adult respiratory distress syndrome). The spectrum of thrombotic events is wide, including in situ pulmonary thrombosis, deep-vein thrombosis and associated pulmonary embolism, as well as arterial thrombotic events (stroke, myocardial infarction, limb artery thrombosis). Unusual thrombotic events have also been reported, e.g., cerebral venous sinus thrombosis, mesenteric artery and vein thrombosis. Several hematology abnormalities have been observed in COVID-19 patients, including lymphopenia, neutrophilia, thrombocytopenia (usually mild), thrombocytosis, elevated prothrombin time and partial thromboplastin times (the latter abnormality often indicating lupus anticoagulant phenomenon), hyperfibrinogenemia, elevated von Willebrand factor levels, and elevated fibrin d-dimer. Many of these abnormal hematologic parameters-even as early as the time of initial hospital admission-indicate adverse prognosis, including greater frequency of progression to severe respiratory illness and death. Progression to overt disseminated intravascular coagulation in fatal COVID-19 has been reported in some studies, but not observed in others. We compare and contrast COVID-19 hypercoagulability, and associated increased risk of venous and arterial thrombosis, from the perspective of heparin-induced thrombocytopenia (HIT), including the dilemma of providing thromboprophylaxis and treatment recommendations when available data are limited to observational studies. The frequent use of heparin-both low-molecular-weight and unfractionated-in preventing and treating COVID-19 thrombosis, means that vigilance for HIT occurrence is required in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.